TIGIT and non-small cell lung carcinoma: The preliminary efficacy of the combination therapy involving the novel anti-TIGIT mAb, tiragolumab, and atezolizumab was evaluated for chemotherapy-naive patients with PD-L1 positive metastatic NSCLC, in the CITYSCAPE trial (Table 1) [62].